JP2007510699A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510699A5
JP2007510699A5 JP2006538890A JP2006538890A JP2007510699A5 JP 2007510699 A5 JP2007510699 A5 JP 2007510699A5 JP 2006538890 A JP2006538890 A JP 2006538890A JP 2006538890 A JP2006538890 A JP 2006538890A JP 2007510699 A5 JP2007510699 A5 JP 2007510699A5
Authority
JP
Japan
Prior art keywords
compound
medicament
iia
administered
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006538890A
Other languages
English (en)
Japanese (ja)
Other versions
JP4740868B2 (ja
JP2007510699A (ja
Filing date
Publication date
Priority claimed from FR0313134A external-priority patent/FR2861991B1/fr
Application filed filed Critical
Publication of JP2007510699A publication Critical patent/JP2007510699A/ja
Publication of JP2007510699A5 publication Critical patent/JP2007510699A5/ja
Application granted granted Critical
Publication of JP4740868B2 publication Critical patent/JP4740868B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006538890A 2003-11-07 2004-11-05 膵線維症の治療のためのグルコシダーゼ阻害剤の使用 Expired - Fee Related JP4740868B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0313134 2003-11-07
FR0313134A FR2861991B1 (fr) 2003-11-07 2003-11-07 Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
PCT/FR2004/002858 WO2005046672A2 (fr) 2003-11-07 2004-11-05 Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose

Publications (3)

Publication Number Publication Date
JP2007510699A JP2007510699A (ja) 2007-04-26
JP2007510699A5 true JP2007510699A5 (cg-RX-API-DMAC7.html) 2007-11-22
JP4740868B2 JP4740868B2 (ja) 2011-08-03

Family

ID=34508347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538890A Expired - Fee Related JP4740868B2 (ja) 2003-11-07 2004-11-05 膵線維症の治療のためのグルコシダーゼ阻害剤の使用

Country Status (24)

Country Link
US (2) US7973054B2 (cg-RX-API-DMAC7.html)
EP (1) EP1680105B1 (cg-RX-API-DMAC7.html)
JP (1) JP4740868B2 (cg-RX-API-DMAC7.html)
KR (2) KR20100038452A (cg-RX-API-DMAC7.html)
CN (1) CN100534432C (cg-RX-API-DMAC7.html)
AT (1) ATE423561T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004289083B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0416228A (cg-RX-API-DMAC7.html)
CA (1) CA2545133C (cg-RX-API-DMAC7.html)
CY (1) CY1110468T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004019674D1 (cg-RX-API-DMAC7.html)
DK (1) DK1680105T3 (cg-RX-API-DMAC7.html)
ES (1) ES2321725T3 (cg-RX-API-DMAC7.html)
FR (1) FR2861991B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20090159T1 (cg-RX-API-DMAC7.html)
IL (1) IL175453A (cg-RX-API-DMAC7.html)
NO (1) NO336904B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ547261A (cg-RX-API-DMAC7.html)
PL (1) PL1680105T3 (cg-RX-API-DMAC7.html)
PT (1) PT1680105E (cg-RX-API-DMAC7.html)
RU (1) RU2358725C2 (cg-RX-API-DMAC7.html)
SI (1) SI1680105T1 (cg-RX-API-DMAC7.html)
WO (1) WO2005046672A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200603726B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
DE602007008870D1 (de) * 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
MX351004B (es) 2006-05-16 2017-09-26 Nat Institutes Of Health Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
AU2009290848A1 (en) * 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of CF-associated mutant Cystic Fibrosis transmembrane conductance regulator
ITFE20080032A1 (it) * 2008-10-23 2010-04-24 Azienda Ospedaliera Istituti Ospit Alieri Di Vero Effetto anti infiammatorio del miglustat cellule dell'epitelio bronchiale
GB201000499D0 (en) 2010-01-13 2010-03-03 Fleet George W J Treatment of cystic fibrosis
WO2011095772A2 (en) 2010-02-04 2011-08-11 Summit Corporation Plc Novel iminosugar therapeutics
GB201006434D0 (en) 2010-04-19 2010-06-02 Summit Corp Plc Novel iminosugar combinations
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
CA2924026C (en) * 2013-09-16 2021-12-28 Emergent Virology Llc Deoxynojirimycin derivatives and methods of their using
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
JP6851964B2 (ja) 2014-09-30 2021-03-31 アミカス セラピューティックス インコーポレイテッド 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ
IL299470B2 (en) 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
US20190391160A1 (en) * 2016-04-29 2019-12-26 Institut Pasteur Methods and compositions for modifying cystic fibrosis transmembrane conductance regulator activity
US10478427B2 (en) * 2016-07-07 2019-11-19 National University Corporation Chiba University Therapeutic agent for fibrosis and inhibitor of nuclear translocation of phosphorylated smad
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
HRP20251697T1 (hr) * 2017-06-01 2026-02-27 Idorsia Pharmaceuticals Ltd Kristalni oblik n-butildeoksigalaktonojirimicina
CN108187051A (zh) * 2018-01-30 2018-06-22 中国药科大学 α-L-岩藻糖苷酶及抑制剂用于制备防治心肌缺血损伤的药物的用途
CN116419754A (zh) * 2020-08-26 2023-07-11 科威里克斯医疗有限公司 用于治疗和预防肺部感染的葡萄糖苷酶抑制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
CA2108584C (en) * 1992-10-27 1998-11-24 James B. Doherty Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1998020123A2 (en) * 1996-11-04 1998-05-14 Institut Curie Stable cell lines expressing the cftr protein or a mutant of this protein, tool for selecting molecules having an effect on the intracellular transport of these proteins
ID21411A (id) * 1997-12-10 1999-06-10 Takeda Chemical Industries Ltd Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU5799500A (en) * 1999-06-29 2001-01-22 Mcgill University Human alpha 1,2-mannosidase
US6476194B1 (en) * 1999-06-29 2002-11-05 National Research Council Of Canada Method for folding unfolded proteins
WO2001021769A2 (en) * 1999-09-23 2001-03-29 Mcgill University THREE-DIMENSIONAL STRUCTURE AND CRYSTAL OF A CLASS I α1,2-MANNOSIDASE, AND METHODS OF USE THEREOF
AU2002359327A1 (en) * 2001-10-30 2003-05-12 Thomas Jefferson University Method of treating viral infections
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
JP5589165B2 (ja) 2003-01-31 2014-09-17 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー タンパク質欠損性障害の治療のための併用療法
US7071341B2 (en) * 2003-02-28 2006-07-04 Council Of Scientific And Industrial Research α-Glucosidase inhibitors and their synthesis from a natural source

Similar Documents

Publication Publication Date Title
JP2007514005A5 (cg-RX-API-DMAC7.html)
JP2004538303A5 (cg-RX-API-DMAC7.html)
JP2005533860A5 (cg-RX-API-DMAC7.html)
JP2005539088A5 (cg-RX-API-DMAC7.html)
JP2005524658A5 (cg-RX-API-DMAC7.html)
JP2006526031A5 (cg-RX-API-DMAC7.html)
JP2006182786A5 (cg-RX-API-DMAC7.html)
JP2007501251A5 (cg-RX-API-DMAC7.html)
JP2003531118A5 (cg-RX-API-DMAC7.html)
JP2009538276A5 (cg-RX-API-DMAC7.html)
JP2006526590A5 (cg-RX-API-DMAC7.html)
TWI315204B (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
JP2009502743A5 (cg-RX-API-DMAC7.html)
TW200911732A (en) Compositions and methods of use for treating or preventing lipid related disorders
JP2002538110A5 (cg-RX-API-DMAC7.html)
JP2009521473A5 (cg-RX-API-DMAC7.html)
JP2008516004A5 (cg-RX-API-DMAC7.html)
RU2006119914A (ru) Применение ингибиторов глюкозидазы для терапии муковисцидоза
JP2005526053A5 (cg-RX-API-DMAC7.html)
JP2008520662A5 (cg-RX-API-DMAC7.html)
JP2011508779A5 (cg-RX-API-DMAC7.html)
ES2296964T3 (es) Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares.
JP2005528398A5 (cg-RX-API-DMAC7.html)
JP2006510632A5 (cg-RX-API-DMAC7.html)
JP2013518061A5 (cg-RX-API-DMAC7.html)